NICE reviews number crunching methods as advanced technologi...

NICE is to review how it develops guidance on drugs, focusing on issues such as modifiers used in decision making and dealing with uncertainties in evidence.

Who will pay the price for inaction on superbugs?

While the UK government has been applauded for its efforts in raising awareness about antimicrobial resistance, its efforts to convince pharma to invest in new antibiotics have so far been

NICE numbers at 20

Leela Barham takes a look at NICE’s stats on Technology Appraisals to see how the agency has changed over it’s 20-year history and what the future might hold.

NICE changes its mind on Novartis’ Kisqali for breast cancer

NICE recommends funding for psoriasis and type 1 diabetes dr...

Patients in England and Wales should soon be able to access AbbVie’s psoriasis drug Skyrizi after NICE recommended regular NHS funding.

NICE restores parity between Alnylam and Akcea on rare disea...